We measured the serum concentrations of moxalactam in 10 children receiving antibiotic prophylaxis for surgery and in 18 children treated for documented or suspected infections. Moxalactam was administered intravenously at a dose of 50 mg/kg every 8 h. After the first dose in 28 patients, mean moxalactam concentrations 5 min, 30 min, 2 h, and 8 h after infusion were 257, 177, 82.2, and 17.5 ,ug/ml, respectively. The mean half-life (T112) was 2.44 h (range: 0.55 to 7.96 h). The mean distribution volume (VD) was 0.30 liters per kg. No significant accumulation was observed with multiple doses. Prophylactic and therapeutic groups had similar serum levels, T112, and VD. The five infants less than 1 year of age had a lower mean 30-min level (P < 0.01), larger VD (P < 0.001) and longer T1/2 (P < 0.025) than the children older than 1 year. A dose of 50 mg/kg produced 30-min levels in excess of 64 ,ug/ml in all patients studied, but 8-h trough levels were below the minimal inhibitory concentration breakpoint of 16 ,g/ml in 32% of patients.
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Moxalactam is a broad-spectrum beta-lactam antibiotic which is gaining increasing use in the treatment of serious pediatric infections. Its activity against gram-negative bacteria, including Haemophilus influenzae (8) , and its penetration into the cerebrospinal fluid (9, 10, 15, 17) make it a reasonable alternative for the treatment of some cases of meningitis. Its activity against Enterobacteriaceae (6, 7, 13, 18) and anaerobes (3) makes it an appealing choice for the treatment of children with ruptured appendix and other intraabdominal infections.
The pharmacology of moxalactam has been extensively studied in healthy adults and in adult patients with normal and impaired renal function (1, 4, 14, 16) . Since studies in children have been much more limited, we examined the pharmacology of moxalactam in healthy children receiving prophylaxis for abdominal surgery, mainly appendectomy, and in seriously ill children receiving therapy for acute infections.
MATERILS AND METHODS
Children from birth to 16 years were eligible for entry into the study. Patients with a history of penicillin or cephalosporin allergy, a history of anaphylaxis to any drug, severe renal insufficiency, or life-threatening infection for which conventional therapy was available were not eligible. Written informed consent was obtained from parents or legal guardians in all cases.
Thirteen children aged 6 to 15 years with a preoperative diagnosis of acute appendicitis received moxalactam as prophylaxis. Three were excluded from analysis because of errors during processing of blood specimens. In 2 of the remaining 10 cases, the diagnosis of appendicitis was not confirmed during surgery: one patient had midgut malrotation and the other had a ruptured corpus luteum cyst. Of the eight patients proven to have acute appendicitis at surgery, two were found to have ruptured appendices for which they received therapeutic courses of moxalactam. Thus, first-dose data were available for 10 and subsequentdose data were available for 2 patients in this group.
Twenty patients, aged 7 days to 16 years, received therapeutic courses of moxalactam for documented or suspected infections (Table 1) . Two patients were excluded from analysis because of thawing of samples before assay. First-dose data were available for all 18 evaluable patients, and subsequent-dose data were available for 10 patients in this group. Dosage and administration. Moxalactam was administered at a dose of 50 mg/kg infused over 30 min every 8 h. Blood samples were obtained by venipuncture or finger/heel puncture at 5, 30, 120, 240, and 480 min after completion of the infusion. Subsequent studies were performed on the third day of therapy. Blood samples were placed on crushed ice immediately after collection. Serum was separated in a 4°C centrifuge and stored at -20°C until assayed. In reconstruction experiments with normal serum, recovery of moxalactam was greater than 90%o after 4 h at room temperature and greater than 90%o after 2 weeks at -20°C. Pak A column; the mobile phase consisted of 32% acetonitrile and 68% Waters Pic-A reagent. Total drug content was measured spectrophotometrically at 270 nM by a peak-height ratio analysis, using cefamandole as an internal standard. The standard curve was linear from 20 to 150 ,Lg/ml. Susceptibility testing. Criteria for susceptibility were a zone of inhibition a20 mm by disk diffusion testing (2), using a 30-Sg disk (Eli Lilly & Co., Indianapolis, Ind.) or a minimal inhibitory concentration (MIC) of <16 p.g/ml by tube dilution assay.
Laboratory testing. Complete blood count, electrolytes, and blood urea nitrogen or creatinine were performed at the start of the study and repeated at least weekly if moxalactam was administered for more than 3 days. Prothrombin time, partial thromboplastin time, transaminases, bilirubin, serum protein determinations, and platelet counts were performed on all patients receiving therapeutic courses of moxalactam.
Pharmacokinetic analysis. Although serum concentrations appeared to decrease in a biexponential fashion over time, there were insufficient data points in the early distribution phase to allow performance of a valid two-compartmental analysis (5, 12 p.g/ml at 5 min, 177 ,ug/ml at 30 min, 82.2 ,ug/ml at 2 h, 49.3 ,ug/ml at 4 h, and 17.5 ,ug/ml at 8 h. All patients had 30-min peak levels greater than 64 ,ug/ml (four times the MIC breakpoint of 16 1Lg/ml). Of 25 patients with measured 8-h levels, trough concentrations were less than 8 ,ug/ml in 5 patients (20%), between 8 and 16 ,ug/ml in 12 patients (48%), and greater than 16 ,ug/ml in 8 patients (32%). The mean T1/2 was 2.44 h, and the mean VD was 0.298 liters/kg.
For children 1 year of age or older, the pharmacology of moxalactam was virtually identical in the prophylactic and therapeutic groups (Table 2). Therefore, data from these two groups were pooled for subsequent comparisons. When compared with children 1 year of age or older, infants had significantly lower 30-min moxalactam levels (P < 0.01) ( Table 2 ). The mean T112 was prolonged (P < 0.025), reflecting both a larger mean VD (P < 0.001) and a slower clearance rate (P < 0.01) in the infant group.
Data for day 1 and day 3 studies appear in Two patients had unsatisfactory results: one patient with nephrotic syndrome who was receiving corticosteroids had moxalactam-susceptible Klebsiella pneumoniae bacteremia and wound sepsis and died after 10 days of moxalactam and amikacin therapy, although blood cultures were negative at the time of death; the other patient with a subphrenic abscess had a superinfection with enterococci while on thera-PY.
Untoward reactions were limited to an urticarial rash in one patient who had never received any antibiotic in the past, and a nonurticarial drug eruption in one patient who subsequently received a beta-lactam antibiotic without incident. We observed no alteration in renal function, no elevation of hepatic enzymes, no neutropenia, and no prolongation of prothrombin time in our study patients. One patient with biliary atresia and abnormal liver function actually showed improvement of liver function tests while on moxalactam therapy. DISCUSSION We found that children receiving moxalactam at a dose of 50 mg/kg every 8 h uniformly achieved 30-min postinfusion levels greater than 64 ,ug/ml. The mean T112 was 2.44 h, but there was marked interpatient variation (range: 0.55 to 7.96 h). Therefore, trough levels were also variable, and 32% of patients had levels below the MIC breakpoint of 16 jig/ml at 8 h.
Serum levels and T1/2 were similar in the seriously ill children with infections and in the surgical prophylaxis patients, and we found no evidence of drug accumulation over the 3-day study period in these patients with normal renal function. However, we did observe age-related changes in pharmacology. Children less than 1 year of age had significantly lower peak and 30-min levels, longer T1/2, larger VD, and slower clearance rates than older children given the same dose. The two neonates in this group had T1/2 and VD values similar to those of the infants In general, our results support the preliminary dosage recommendations of other investigators (9, 15) and of the manufacturer (package insert). The recommended dose of 50 mg/kg reliably produced 30-min levels of 64 ,ug/ml (four times the MIC breakpoint) in infants, and serum concentrations were well above this level in children older than Moxalactam has proven to be a safe and effective antibiotic in our study. Although we observed a 26% relapse/reinfection rate and a 10%o failure rate, our patients were often seriously ill, many having been preselected by their failure to improve on other regimens. Still, it is clear that moxalactam, as well as the other "third-generation" beta-lactams, has limitations, and its exact place in the armamentarium of antimicrobial agents will be more clearly defined as experience with it is accumulated.
